ClinicalTrials.Veeva

Menu
S

Strathfield Retina Clinic | Strathfield, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
APL-2
JNJ-81201887
KHK4951
Triamcinolone Acetonide
Aflibercept
Ranibizumab
Pegcetacoplan
Dexamethasone
IBE-814

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 21 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: Faricimab

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Active, not recruiting
Choroidal Neovascularization Secondary to Pathologic Myopia
Procedure: Sham Procedure
Drug: Faricimab

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

Trial sponsors

Roche logo
A
C
Janssen (J&J Innovative Medicine) logo
Kyowa Kirin logo
Bayer logo
Ionis Pharmaceuticals logo
McMaster University logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems